Telix Pharmaceuticals Limited (TLPPF)

Market Cap	6.33B
Revenue (ttm)	484.69M
Net Income (ttm)	30.89M
Shares Out	n/a
EPS (ttm)	0.09
PE Ratio	204.85
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,200
Average Volume	3,221
Open	18.75
Previous Close	17.50
Day's Range	18.75 - 19.25
52-Week Range	7.00 - 19.25
Beta	2.41
RSI	63.54
Earnings Date	Feb 19, 2025

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 234
• Stock Exchange: OTCMKTS
• Ticker Symbol: TLPPF

Financial Performance

In 2024, Telix Pharmaceuticals's revenue was 783.21 million, an increase of 55.85% compared to the previous year's 502.55 million. Earnings were 49.92 million, an increase of 857.95%.

Financial numbers in AUD